Clinical Trial: Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07225972) titled 'Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone' on Nov. 04.

Brief Summary: Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.

Study Start Date: Dec. 01, 2026

Study Type: INTERVENTIONAL

Condition: CMV AdV Infection AdV Reactivation Adenovirus Cytomegalovirus Infections

Intervention: DRUG: Standard of Care Antiviral medications

Standard of Care medications will be selected by the tre...